Search

Anavex Life Sciences Corp

Chiusa

SettoreSettore sanitario

1.52 -0.65

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.51

Massimo

1.6

Metriche Chiave

By Trading Economics

Entrata

14M

7.8M

EPS

0.08

Dipendenti

34

EBITDA

3.3M

-3.2M

Dividendi

By Acuity

Utili prossimi

24 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-136M

152M

Apertura precedente

2.17

Chiusura precedente

1.52

Notizie sul Sentiment di mercato

By Acuity

91%

9%

311 / 340 Classifica in Healthcare

Anavex Life Sciences Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 ott 2026, 22:20 UTC

Anavex Life Sciences Corp saw a sharp increase in after-market hours on Wednesday, recovering from an earlier dip and achieving a high cumulative return.

6 ott 2026, 20:00 UTC

News

Anavex Life Sciences Corp shares fell sharply amid increased scrutiny from class action lawsuits alleging securities fraud related to the company's operations and internal controls.

5 ott 2026, 20:01 UTC

News

Anavex Life Sciences Corp faces a class action lawsuit alleging false statements, contributing to a sharp decline in shares after an initial rise today.

2 ott 2026, 19:35 UTC

News

Anavex Life Sciences Corp faces a class action lawsuit over alleged misconduct, contributing to a continued decline in shares amid negative sentiment.

1 ott 2026, 20:06 UTC

News

Anavex Life Sciences Corp shares fell sharply amid multiple investigations and class action lawsuits related to alleged securities fraud and internal control weaknesses.

30 set 2026, 23:20 UTC

Anavex Life Sciences Corp is moving higher in after-market trading, reflecting a broader market advance following a revised Q2 GDP growth rate of 2.2%.

29 set 2026, 19:36 UTC

Anavex Life Sciences Corp shares are higher in the current session, gaining since Monday, though they remain below their 20-day moving average.

25 set 2026, 20:01 UTC

Anavex Life Sciences Corp is experiencing an upward movement, gaining ground since Thursday's close, though still below its 20-day moving average.

24 set 2026, 19:35 UTC

Anavex Life Sciences Corp is trading roughly flat, reflecting little change since Wednesday's close amid a broader market decline over the past month.

23 set 2026, 23:10 UTC

Anavex Life Sciences Corp is up in after-market trading, gaining ground since Wednesday's close despite remaining below its 20-day moving average.

16 set 2026, 19:46 UTC

Anavex Life Sciences Corp shares fell sharply, continuing an eight-session decline and reaching a new low, remaining well below the 20-day moving average.

15 set 2026, 20:03 UTC

News

Anavex Life Sciences Corp shares declined as PVG Asset Management criticized the board's governance, urging shareholders to support their nominees amid perceived failures.

10 set 2026, 20:07 UTC

News

Anavex Life Sciences shares are lower as PVG Asset Management plans a proxy campaign to change the board, citing concerns over governance and leadership.

9 set 2026, 19:46 UTC

News

Anavex Life Sciences shares decline as PVG Asset Management calls for a board replacement, citing concerns over inexperience and funding issues for upcoming trials.

8 set 2026, 20:21 UTC

Anavex Life Sciences Corp shares are lower in after-market trading, declining significantly below the 20-day moving average and near the lower end of its one-month range.

4 set 2026, 19:46 UTC

News

Anavex Life Sciences is rising as PVG Asset Management proposes changes to its Board of Directors, aiming to enhance governance and accountability.

3 set 2026, 19:46 UTC

News

Anavex Life Sciences has regained Nasdaq compliance but shares are lower. The stock remains below its 20-day moving average amid broader market sentiment.

2 set 2026, 21:01 UTC

News

Anavex Life Sciences regained compliance with Nasdaq rules after filing overdue reports. Shares are lower in after-market trading, reflecting broader market dynamics.

1 set 2026, 19:54 UTC

Anavex Life Sciences Corp shares are trading higher today, recovering from an early dip amid broader market pressures and rising Treasury yields.

31 ago 2026, 21:01 UTC

Anavex Life Sciences Corp is trading higher in after-market hours, rebounding from earlier lows after five sessions of declines.

28 ago 2026, 19:16 UTC

Anavex Life Sciences Corp. shares are lower today, extending a three-session decline amid broader market concerns over inflation and corporate growth expectations.

27 ago 2026, 22:01 UTC

Anavex Life Sciences Corp is rising in after-hours trading, continuing a gradual ascent since Thursday's close, despite broader market conditions and no specific news.

26 ago 2026, 23:41 UTC

Anavex Life Sciences Corp shares are higher during after-market hours, supported by a broader market trend. No specific company news was identified.

25 ago 2026, 20:07 UTC

Event
News

Anavex Life Sciences reported Q3 2026 net income of $7.8 million, returning to profitability. Shares are trading higher following the financial results and pipeline updates.

24 ago 2026, 23:11 UTC

Anavex Life Sciences Corp shares are higher in after-market trading, building on positive momentum from Monday's close and a strong one-month performance.

21 ago 2026, 20:06 UTC

Anavex Life Sciences Corp is gaining amid broader market strength, reflecting a robust performance in biotechnology and positive investor sentiment despite no specific company news.

20 ago 2026, 20:01 UTC

Anavex Life Sciences Corp shares are lower today, driven by significant weakness in the Biotechnology sub-sector and broader trends affecting the sector.

19 ago 2026, 19:44 UTC

Anavex Life Sciences Corp is trading sharply higher, reaching a session high and maintaining a position above its 20-day moving average. No specific news was identified.

17 ago 2026, 19:46 UTC

News

Anavex Life Sciences has communicated with stockholders about director nominees amid a "Hold" rating from analysts. Shares are trading roughly flat since Friday's close.

14 ago 2026, 20:13 UTC

Anavex Life Sciences shares are lower in after-market hours, influenced by disappointing U.S. retail sales data and declining consumer sentiment.

Confronto tra pari

Modifica del prezzo

Anavex Life Sciences Corp Previsione

Consenso sulla valutazione

By TipRanks

0 ratings

0

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

311 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.